29 April 2010
Approval of patent in Europe
Glucox Biotech has been approved its third patent application in Europe in April 2010. The examining Division has granted the European patent that will cover the use of NAD(P)H oxidase inhibitors as a medicament in the treatment and/or prevention of diseases caused by diabetes.
The patent received will provide a strong commercial protection for pharmaceutical products proceeding within the company and adds extended value to the existing IP-portfolio of Glucox Biotech.
Glucox Biotech is currently testing its novel compounds in animal tests and is preparing for a clinically applicable therapeutic drug for treatment of type 2 diabetes and insulin resistance as well as diabetes complications.
15 April 2010
Initiation of aminal studie case for novel compounds
Glucox Biotech has initiated a comprehensive animal study to confirm a proof-of-concept with the selected compounds of interest based on the screening compound from the potential hit series that resulted in few very promising chemical series amenable for lead generation.
Pressrelease 15 May 2007
Promising Results in Treatment with GLX
Pressrelease 29 December 2006
US Patent Received for Diabetes Treatment
Pressrelease 28 September 2006
Glucox' Unique Research Discovery Confirmed by US Scientist
Pressrelease 10 July 2006
Patent Application Submitted for the GLX Compounds
Pressrelease 5 June 2006
A Significant Preclinical Milestone Achieved
Pressrelease 7 February 2006
Positive Results from the First Time In Animal Study
Pressrelease 10 January 2006
Pressrelease 10 November 2005
Evaluation and Selection of Glucox Biotech' Lead Drug Candidates